Abstract 198P
Aim/Background
Among standard chemotherapy regimens for advanced gastric cancer; capecitabine plus cisplatin (XP) and S-1 plus cisplatin (SP) were comparable in a multicenter randomized phase II trial, XParTS II. This study was designed to identify molecular biomarkers for XP and SP in the trial.
Methods
Paraffin-embedded primary tumor specimens were collected in 98 of 116 randomized patients in XParTS II. The mRNA was measured with a real-time PCR for thymidine phosphorylase (TP), dihydropyrimidine dehydrogenase (DPD), orotate phosphoribosyltransferase (OPRT), and thymidylate synthase (TS), and categorized at median into low or high subgroups in order to analyze their association with efficacy endpoints.
Results
Baseline demographic and clinical characteristics of the subjects were similar to the results of the original trial. There was no significant difference in each marker between XP and SP groups; while TP was higher in samples from patients with measurable lesions, and TS was higher in patients with intestinal type and measurable tumors. In comparison for efficacy between XP and SP groups, there was no interaction for PFS and TTF for each marker. While for OS, OPRT was associated with efficacy of the treatment regimens; for XP vs. SP, hazard ratios were 2.0 and 0.73 for low and high mRNA, respectively (P = 0.098 for interaction).
Conclusions
OPRT is suggested to be a candidate predictive biomarker for the first-line treatment of advanced gastric cancer by XP or SP. Further examination is warranted to confirm these results in other clinical trials and/or cohort studies.
Clinical trial identification
NCT0140624
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
Vitamin D3 (cholecalciferol) acts as a negative regulator of breast cancer cell invasiveness in the absence of activation of classical VDR signalling
Presenter: MD Musharraf Hossain
Session: Poster presentation 1
Resources:
Abstract
VCP/p97 inhibition is a therapeutic strategy to overcome drug resistance in ovarian and pancreatic cancers
Presenter: Yuliana Astuti
Session: Poster presentation 1
Resources:
Abstract
Upregulation of the interleukin 17/granulocyte-colony stimulating factor/fibroblast growth factor axis and its correlation with indoleamine 2,3-dioxygenase in breast cancer
Presenter: Kosuke Kawaguchi
Session: Poster presentation 1
Resources:
Abstract
Updated analysis: Phase II trial of irinotecan plus S-1 (IRIS) with cetuximab (IRIS/Cet) in pre-treated patients with KRAS wild type metastatic colorectal cancer (mCRC): HGCSG0902
Presenter: Ayumu Hosokawa
Session: Poster presentation 1
Resources:
Abstract
Updated analysis: observational cohort study of 1st line bevacizumab combined with chemotherapy in metastatic colorectal cancer (HGCSG0802): Comparison of infusional FU/oxaliplatin (OX) + BV and oral FU/OX + BV
Presenter: Yoshito Komatsu
Session: Poster presentation 1
Resources:
Abstract
Tuberculosis exposure and the risk of cancer
Presenter: Vincent Yi-Fong Su
Session: Poster presentation 1
Resources:
Abstract
Triple negative breast cancer and androgen receptor expression: a forerunner for a novel hormonal approach
Presenter: Prameela Chelakkot G
Session: Poster presentation 1
Resources:
Abstract
Treatment of radiation induced side-effects in prostate cancer patients with hyperbaric oxygen therapy
Presenter: HAYATO Takeda
Session: Poster presentation 1
Resources:
Abstract
Tolerability and efficacy of neoadjuvant chemotherapy with three-weekly interval methotrexate, doxorubicin, vinblastine and cisplatin regimen for patients with locally advanced bladder cancer
Presenter: Satoko Arai
Session: Poster presentation 1
Resources:
Abstract
To compare the efficacy and safety of pazopanib and sunitinib in metastatic renal cell carcinoma (RCC) of Chinese population
Presenter: Michelle Fong Ting Chan
Session: Poster presentation 1
Resources:
Abstract